Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ELVN vs MIRM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ELVN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

ELVN Overall Winner 6-Pillar Tally: ELVN 3 – 2 MIRM (1 Tie) Matrix Metrics: ELVN 4 – 4 MIRM

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Mirum Pharmaceuticals, Inc. (MIRM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas MIRM carries 38.1/100 (SELL) at $92.92 (N/M Forward P/E, -21.6% operating margin).

  • Composite vs. Pillar Nuance: While MIRM currently prints a higher short-term Unified Composite Score (38.1/100 SELL vs. ELVN 35.9/100 SELL), ELVN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -21.6% operating margin) and revenue trajectory (+0.0% vs. +39.6% YoY).
  • Defensive Composite Rating Caution: Although ELVN compares more favorably head-to-head, both ELVN (35.9/100 SELL) and MIRM (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile MIRM is in a Breakdown options structure phase (RSI 58.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELVN vs MIRM
ELVN NASDAQ Head-to-Head Winner
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 60% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $45.78 · SMA50: $46.20
MIRM NASDAQ
Mirum Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$92.92
-1.14% 1D
Market Cap $6.1B
TTM Revenue $671M
Forward P/E N/M
Beta / 30D Vol 1.02β · 49% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 8.0 Fund 37.0 Flow 71.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.1 · SMA20: $88.89 · SMA50: $88.64

6-Pillar Scorecard Institutional Category Breakdown (ELVN 3 – 2 MIRM)

Columns: Metric · ELVN · MIRM
1. Valuation Multiples MIRM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.8x
2. Growth & Scale MIRM
Revenue Growth (YoY) +0.0% +39.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $671M
Market Cap $3.6B $6.1B
3. Profitability & Quality ELVN
Gross Margin N/A 81.7%
Operating Margin 0.0% -21.6%
Net Profit Margin 0.0% -134.8%
Return on Equity (ROE) -16.8% -760.0%
4. Balance Sheet & Cash Flow ELVN
Cash Generation (TTM) -$66M -$309M
Cash Flow Margin N/A -46.0%
Net Cash / Leverage $150M Net Cash $500M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ELVN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 46.9% (5th %ile) 72.6% (9th %ile)
Put/Call OI Skew 1.67x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELVN (4) vs MIRM (4)
Institutional Metric ELVN MIRM Criterion Row Edge
Market Capitalization
Scale
$3.6B $6.1B Larger Scale MIRM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +39.6% Higher Growth MIRM
Operating Margin (TTM)
Profitability
0.0% -21.6% Higher Margin ELVN
Net Profit Margin
Profitability
0.0% -134.8% Higher Margin ELVN
Return on Equity (ROE)
Capital Efficiency
-16.8% -760.0% Higher ROE ELVN
52-Week Range Position
Momentum
69% ($15–$62) 44% ($63–$130) Stronger Trend ELVN
Beta / 30D Volatility
Risk Regime
0.96β · 60% Vol 1.02β · 49% Vol Lower Realized Risk MIRM
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 38.1 / 100 (SELL) Higher Composite MIRM
Trailing 12M Revenue (USD)
Operating Scale
N/A $671M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 81.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($150M Net Cash) -$309M ($500M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELVN +11.44 pp
ELVN: +27.38% · MIRM: +15.94%
3M Horizon MIRM +12.97 pp
ELVN: -20.86% · MIRM: -7.89%
6M Horizon ELVN +22.66 pp
ELVN: +19.96% · MIRM: -2.7%
1Y Horizon ELVN +100.36 pp
ELVN: +134.53% · MIRM: +34.17%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs MIRM. Trailing 12-month operating profitability (ELVN 0.0% vs MIRM -21.6%) and valuation multiples (ELVN N/M vs MIRM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ELVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-16.8% · N/M
MIRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$671M
Gross Margin81.7%
Op. Margin-21.6%
ROE / Fwd P/E-760.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELVN CONSOLIDATION
59d in phase · OBV NEUTRAL
Current IV 46.9%
IV Percentile 5th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MIRM BREAKDOWN
92d in phase · OBV NEUTRAL
Current IV 72.6%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MIRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MIRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.1B market capitalization and -21.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ELVN vs MIRM Key Questions & Quantitative Answers

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Mirum Pharmaceuticals, Inc. (MIRM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas MIRM carries 38.1/100 (SELL) at $92.92 (N/M Forward P/E, -21.6% operating margin). Composite vs. Pillar Nuance: While MIRM currently prints a higher short-term Unified Composite Score (38.1/100 SELL vs. ELVN 35.9/100 SELL), ELVN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -21.6% operating margin) and revenue trajectory (+0.0% vs. +39.6% YoY). Defensive Composite Rating Caution: Although ELVN compares more favorably head-to-head, both ELVN (35.9/100 SELL) and MIRM (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile MIRM is in a Breakdown options structure phase (RSI 58.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MIRM leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MIRM at +39.6% YoY revenue growth and +0.0% YoY earnings growth on $671M TTM revenue (81.7% gross margin, -21.6% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus $671M for MIRM. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MIRM.

MIRM screens cheaper on headline valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MIRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.8x EV/Revenue (-46.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus MIRM (-760.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, MIRM carries 72.6% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.